Exemestane dosage film-coated tablets containing 145 mg of micronized fenofibrate nanoparticle. Source fenofibrate in plasma can not be detected. The major plasma metabolite is fenofibric acid.
Suction: maximum plasma concentration achieved within 2-4 hours after ingestion. With prolonged use of the drug concentration in the plasma remains stable regardless of the individual patient.Unlike previous fenofibrate formulations, the maximum plasma concentration and the total effect of fenofibrate nanoparticle is independent of food intake. Therefore Traykor 145 mg can be taken at any time, regardless of the meal.
Fenofibric acid binds strongly to plasma albumin (more than 99%).
The half-life of fenofibric acid 20 hours.
Metabolism and excretion: After oral administration, fenofibrate is rapidly hydrolyzed by esterases. The plasma is found only major active metabolite of fenofibrate – fenofibric acid. Fenofibrate is not a substrate . Do not participate in the microsomal metabolism.
It is shown mainly in the urine in the form of fenofibric acid and the glucuronide conjugate. During the 6 days of fenofibrate appears almost completely. The total clearance of fenofibric acid, determined not altered in elderly patients.
The drug is not cumulated after a single dose and long-term use. When hemodialysis is not deduced.
Hypercholesterolemia and hypertriglyceridemia isolated or mixed exemestane dosagein patients for whom diet and other non-drug therapeutic measures (eg weight reduction or increased physical activity) have been ineffective, especially in the presence of dyslipidemia-related risk factors such as hypertension and smoking.
For the treatment of hyperlipoproteinemia secondary drug is used in cases where hyperlipoproteinemia persists despite effective treatment of the underlying disease .
The drug is strictly contraindicated in the following cases:
- Hypersensitivity to fenofibrate or other components of the drug
- liver failure (including cirrhosis),
- severe renal insufficiency exemestane dosage
- age of 18 years (effectiveness and safety have been established),
- a history of photosensitivity or phototoxicity during treatment with fibrates or ketoprofen,
- gallbladder disease,
- congenital galactosemia, lactase deficiency, malabsorption of glucose and galactose (a drug contains lactose)
- congenital fruktozemiya, sucrase-isomaltase insufficiency (the drug contains sucrose)
- allergic to peanuts, peanut oil, soy lecithin or a history of related products (due to the risk of hypersensitivity reaction).
in hepatic and / or renal failure, hypothyroidism; patients who abuse alcohol, the elderly, burdened with a history of hereditary muscular diseases on; while receiving oral anticoagulants, reductase inhibitors (see. “Interaction with other medicinal products” section).
Pregnancy and lactation
There are limited data on the use of fenofibrate in pregnant women. In animal experiments, a teratogenic effect of fenofibrate was observed. Embryotoxicity was observed when administered during preclinical trials doses toxic to the mother’s body. The potential risk for humans is unknown. Therefore, during pregnancy Traykor tablets 145 mg may be used only after careful evaluation of the risk-benefit ratio.
The drug is contraindicated during breast-feeding (insufficient data on the use of the drug during this period).
Dosing and Administration
Traykora tablets 145 mg should be swallowed whole without chewing, washing down with water. Traykor 145 mg can be taken at any time of the day, regardless of meals.
Adults. By Traykora one tablet 145 mg once a day.
Patients taking one capsule of 200 mg of fenofibrate or one tablet of fenofibrate 160 mg daily, can go to the reception of 1 tablet Traykora 145 mg without further dose adjustment.
Elderly patients. It is recommended to take a unit dose for adults exemestane dosage.